MedTrace Logo

Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making

NCT02526914 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 432

Last updated 2015-08-18

No results posted yet for this study

Summary

The purpose of this study is to investigate the role of a one-time intranasal administration of the oxytocin, vasopressin, or placebo on prosocial decision making such as cooperation and competition in a healthy population of student controls.

Conditions

  • Healthy

Interventions

DRUG

Intranasal Oxytocin

Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).

DRUG

Intranasal vasopressin

Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).

DRUG

Intranasal placebo

Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.

Sponsors & Collaborators

  • Hebrew University of Jerusalem

    collaborator OTHER

  • David Mankuta

    lead OTHER

Principal Investigators

  • David Mankuta, MD · Hadassah University Medical Organization

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-07-31
Completion
2017-10-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02526914 on ClinicalTrials.gov